Latest / Pharmacy Podcast Network / Into the Volcano: AI and Data Privacy within the Specialty Pharmacy Space | NASP Specialty Podcast
Transcript
- 0:05Speaker 1: You are listening to the global network of podcasters dedicated
- 0:09Speaker 1: to the pharmacy profession. Welcome to the Pharmacy Podcast Network.
- 0:25Speaker 2: You are listening to the NASP podcast. This Specialty Pharmacy
- 0:30Speaker 2: podcast is a collaboration with the National Association of Specialty
- 0:34Speaker 2: Pharmacy and the Pharmacy Podcast Network. The mission of the
- 0:37Speaker 2: National Association of Specialty Pharmacy is to improve specialty pharmacy
- 0:41Speaker 2: practice by promoting continuing professional education and certification of specialty
- 0:47Speaker 2: pharmacists while advocating for public policies that ensure patient access
- 0:51Speaker 2: to specialty medications. As the healthcare industry's leading podcasts dedicated
- 0:56Speaker 2: to the pharmacy profession, the Pharmacy Podcast Network is proud
- 1:00Speaker 2: to bring our listeners the NASP Podcast in collaboration with
- 1:04Speaker 2: the National Association of Specialty Pharmacy.
- 1:07Speaker 3: Hello, my name Mishila Arquette and I'm the President and
- 1:09Speaker 3: CEO of the National Association of Specialty Pharmacy. I am
- 1:12Speaker 3: delighted to welcome two very special guests, Simone Colden Dunlap
- 1:16Speaker 3: and Candice Luherman to this episode of the NSP podcast.
- 1:20Speaker 3: Simone Colgan Dunlap is National Vice Chair of the Quarrel's
- 1:24Speaker 3: Health and Sciences practice Group and leads the firm's Specialty
- 1:27Speaker 3: Pharmacy Industry Group. Simone's practice is focused on regulatory compliance, related,
- 1:32Speaker 3: risk management and corporate contracting matters for a variety of clients,
- 1:37Speaker 3: with a particular emphasis on specialty pharmacy. Simone provides practical
- 1:42Speaker 3: and strategic advice to clients on a diverse array of
- 1:45Speaker 3: regulatory compliance issues, including artificial intelligence HIPPA, state privacy laws
- 1:52Speaker 3: AKS CMP, and state pharmacy laws. She also has significant
- 1:57Speaker 3: experience drafting and negotiating agreements, including distribution agreements, BAAS, GPO agreements,
- 2:04Speaker 3: data use agreements, licensing agreements, specialty pharmacy services agreements of agreements,
- 2:10Speaker 3: marketing agreements, risk evaluation mitigation strategies, consulting agreements, independent contractor agreements,
- 2:18Speaker 3: and numerous other commercial contracts. She graduated Cu laude from
- 2:23Speaker 3: the University of Michigan Law School. Kennice Lherman is a
- 2:27Speaker 3: passionate advocate who utilizes her vast experience and healthcare to
- 2:30Speaker 3: solve complex problems. She's been recognized for her work on
- 2:34Speaker 3: behalf of Patient communities and on Capitol Hill, leveraging her
- 2:38Speaker 3: knowledge as a rare disease patient and attorney. She has
- 2:41Speaker 3: worked with various stakeholders and life sciences to develop programs
- 2:45Speaker 3: that better serve patients in all aspects of the product
- 2:48Speaker 3: life cycle. Candice earned her Juris Doctor from the Shepherd
- 2:53Speaker 3: Broad College of Law at Nova Southeastern University. She also
- 2:57Speaker 3: holds a Bachelor and Master of Science in International Affairs
- 3:01Speaker 3: from Florida State University. Simaning, Candice, thanks so much for
- 3:05Speaker 3: joining me today.
- 3:07Speaker 4: Thanks thanks for having us.
- 3:09Speaker 3: Quite impressive, ladies, these bios quite impressive to start off with.
- 3:13Speaker 3: Can you please provide a brief overview of what we're
- 3:17Speaker 3: talking about when we say AI.
- 3:20Speaker 5: Sure, I'll start so artificial intelligence or AI. It's a
- 3:27Speaker 5: complex definition in my opinion, because I think everybody has
- 3:30Speaker 5: their own bias of what AI is.
- 3:32Speaker 4: To me, AI is.
- 3:33Speaker 5: Sort of a computer system or some sort of software
- 3:37Speaker 5: function that can analyze data and information and then provide
- 3:42Speaker 5: some sort of output, whether it be a decision, an analysis,
- 3:47Speaker 5: or some kind of unique data set after comprehensively examining
- 3:56Speaker 5: whatever you give it. On the other side of it,
- 3:59Speaker 5: artificial intelligence has also been historically automated processes that can
- 4:05Speaker 5: replace some sort of human action, and we've seen this
- 4:12Speaker 5: actually for decades, we just didn't really realize what AI was.
- 4:14Speaker 5: Because now AI is the new hot topic.
- 4:18Speaker 4: The buzzword.
- 4:19Speaker 6: Yes, absolutely, it is very buzzy. And Cannescyra is a
- 4:24Speaker 6: great point the definition of AI from our regulatory standpoint,
- 4:28Speaker 6: because we're lawyers, know we're really interested in how a
- 4:30Speaker 6: law defines AI. The FDA has a definition, but there
- 4:35Speaker 6: isn't one agreed upon definition of AI when you look
- 4:38Speaker 6: at different regulatory schemes. So that is a challenge that
- 4:41Speaker 6: industry stakeholders face when they're trying to talk about AI.
- 4:45Speaker 6: You kind of have to define what do you mean
- 4:46Speaker 6: when you say AI? What does it mean in this context?
- 4:50Speaker 6: And the other great point you hit on is that
- 4:53Speaker 6: there's a lot of excitement around AI products and there's
- 4:56Speaker 6: a lot of claims proliferating in the market regarding what
- 4:59Speaker 6: AI is, what your AI quote product can do. So
- 5:03Speaker 6: it's a marketing term as well, and we've seen the
- 5:05Speaker 6: FTC get very interested in how people are making claims
- 5:08Speaker 6: about AI. So in addition to it being kind of
- 5:12Speaker 6: a technical legal term, we're also seeing it being used
- 5:14Speaker 6: as that marketing term.
- 5:18Speaker 3: So are there specific laws, regulations, or other guidance appreciating
- 5:22Speaker 3: that right, there isn't I guess a universally accepted definition
- 5:25Speaker 3: of AI similar specialty pharmacy that governs AI use.
- 5:29Speaker 6: Oh gosh. Yeah, there's a lot of guidance in different
- 5:33Speaker 6: regulatory schemes that touch on AI. There's no overarching federal like,
- 5:38Speaker 6: this is our approach to AI, this is our comprehensive
- 5:41Speaker 6: regulation of AI. This is how we're going to preempt
- 5:44Speaker 6: all state law. There's no law that's like that. But
- 5:48Speaker 6: I think one thing that is really interesting and may
- 5:51Speaker 6: not be apparent to people, but there's a lot of
- 5:52Speaker 6: existing regulatory schemes in place as well as those that
- 5:56Speaker 6: are specific to AI. We've seen states come out Utah
- 6:00Speaker 6: and Colorado and California that have individual AIX or have
- 6:04Speaker 6: included AI and their rulemaking. But you also have laws
- 6:09Speaker 6: like HIPPO or the fea's regulation of medical devices. These
- 6:13Speaker 6: are historical regulatory schemes, but they touch on AI and
- 6:17Speaker 6: they impact AI. So to the extent that you are
- 6:20Speaker 6: developing a product or a service that uses AI, you
- 6:23Speaker 6: have to be very cognizant not only of the laws
- 6:26Speaker 6: that say AI and the title, but also existing regulatory schemes.
- 6:33Speaker 3: So how do current healthcare regulatory schemes. That's an interesting
- 6:37Speaker 3: term right to me, as like a negative apply to
- 6:41Speaker 3: AI tools used in specialty pharmacy.
- 6:45Speaker 6: Great question, Sheila Cannie. Do you want to jump in here,
- 6:48Speaker 6: I don't want to.
- 6:49Speaker 4: Yeah.
- 6:49Speaker 5: So, in my experience, especially as in house council and
- 6:54Speaker 5: dealing with developing AI tools for pharmacists to leverage, especially
- 6:59Speaker 5: in ptient interactions, data privacy is the biggest hurdle.
- 7:05Speaker 4: You know, you're dealing with HIPPA.
- 7:06Speaker 5: As Simone mentioned, that's that's just something that I don't
- 7:09Speaker 5: think we'll ever get away from. You're looking at overall
- 7:12Speaker 5: data privacy laws too. At the state level. I get
- 7:14Speaker 5: a lot of questions about California's data privacy laws or
- 7:18Speaker 5: other state data privacy laws that maybe don't necessarily mention
- 7:22Speaker 5: AI directly, but they're dealing with patient data privacy and
- 7:26Speaker 5: for specialty pharmacies, that's kind of the complex mind field
- 7:31Speaker 5: that you know you're facing on it on a daily
- 7:35Speaker 5: basis or when you're examining the potential to implement AI
- 7:38Speaker 5: tools in software within your pharmacy. And I'd say too,
- 7:42Speaker 5: the other thing that we're going to be looking at
- 7:45Speaker 5: with the new administration coming in here in January, is
- 7:48Speaker 5: what changes could we see from a regulatory landscape. We
- 7:52Speaker 5: just had yesterday the Congression, the Congressional AI Task Force
- 7:56Speaker 5: released their report and starting on page two hundred, there's
- 8:00Speaker 5: an entire section dealing with artificial intelligence and healthcare and
- 8:05Speaker 5: it talks through many different facets, but one thing was
- 8:08Speaker 5: clinical decision making, which I know for a lot of
- 8:10Speaker 5: specialty pharmacies there's questions about, well, when we're dealing with regulations,
- 8:15Speaker 5: we're looking at the Food, Drug and Cosmetic Act, we're
- 8:17Speaker 5: looking at FTC guidelines, what does clinical decision making AI
- 8:22Speaker 5: tools present in terms of risks? And it really just
- 8:26Speaker 5: comes down to the classic legal answer of it depends.
- 8:30Speaker 5: And I hate that, but that's kind of the that's
- 8:33Speaker 5: kind of where we are right now.
- 8:36Speaker 3: So where do you see the biggest challenges to AI
- 8:39Speaker 3: adaption from a legal perspective.
- 8:44Speaker 6: I think that it canice hit on. One of the
- 8:46Speaker 6: biggest ones is privacy and security. So AI systems require
- 8:51Speaker 6: really large data sets and to be able to get
- 8:54Speaker 6: the data sets to ensure that you have the rights
- 8:56Speaker 6: to them, that you're providing the right level of transparency,
- 8:59Speaker 6: that you have consent that's a huge problem. Other legal
- 9:03Speaker 6: issues and challenges we see our liability. There's limited legal
- 9:08Speaker 6: and ethical guidance currently on accountability, Like when AI makes
- 9:13Speaker 6: a mistake, you know, we don't know is the creator
- 9:16Speaker 6: of AI responsible? Is the clinician and responsible? And this
- 9:20Speaker 6: is a problem that snowballs when you have multiple parties
- 9:24Speaker 6: involved in developing and deploying AI systems. It becomes very complex.
- 9:28Speaker 6: So as lawyers, you know, we're always interested when we
- 9:30Speaker 6: create contracts or are navigating relationships and understanding risk allocation,
- 9:34Speaker 6: and not having certainty in the liability space makes it
- 9:38Speaker 6: very challenging. Another key area of managing bias to avoid
- 9:42Speaker 6: discriminatory outcomes. When you're an entity that's involved in developing
- 9:46Speaker 6: and deploying AI systems, there's a real concern about making
- 9:49Speaker 6: sure that you have quality data, that the data is representative.
- 9:53Speaker 6: If you get it wrong. In healthcare, people can have
- 9:55Speaker 6: serious consequences. You can have deaths, you can have injuries,
- 9:59Speaker 6: So making sure that we manage those biaces, especially in healthcare,
- 10:03Speaker 6: is a very significant concern. Another one that's less sexy
- 10:07Speaker 6: is reimbursement. Frankly, Sheila, I'm going to be really interested
- 10:10Speaker 6: as we see AI become more prevalent in the healthcare space,
- 10:13Speaker 6: how are payers going to grapple with this. We've seen
- 10:16Speaker 6: some discussion from cms about this this year already, but
- 10:21Speaker 6: it's going to be really interesting how that reimbursement discussion
- 10:25Speaker 6: becomes more developed over time. And the other thing that
- 10:29Speaker 6: I'll call out with AI that's a real challenge right
- 10:31Speaker 6: now is that the technology is moving so fast. We're
- 10:34Speaker 6: always in a space as lawyers where I feel like
- 10:36Speaker 6: we say that regulation lags after technology. We're always looping
- 10:40Speaker 6: along after the fact. But right now, the pace of
- 10:43Speaker 6: technology is just moving so so quickly, and so figuring
- 10:47Speaker 6: out where future regulation is going to land in future
- 10:50Speaker 6: proof products and thinking for our clients is really a
- 10:54Speaker 6: challenge at this moment.
- 10:57Speaker 5: Yeah, I definitely who want to emphasize Moan's last point.
- 11:01Speaker 5: I think one of the challenges that lawyers are having
- 11:03Speaker 5: right now in this space is really wrapping their minds
- 11:06Speaker 5: around the complexities and also the possibilities that AI presents
- 11:12Speaker 5: for healthcare and to the point with data sets, especially
- 11:15Speaker 5: as a rare disease patient. You know, you're a specialty
- 11:18Speaker 5: pharmacist and you're considering the data sets that you could
- 11:21Speaker 5: be leveraging to help with process automation, clinical decision making.
- 11:26Speaker 5: At the end of the day, pharmacists are still responsible
- 11:29Speaker 5: for the outcomes that AI could help them get to
- 11:33Speaker 5: or reach. And so even though AI is great, there's
- 11:37Speaker 5: still a lot of discussion around will does AI replace
- 11:39Speaker 5: all of us?
- 11:40Speaker 4: Does it replace lawyers? Does it replaced pharmacist? Does it
- 11:42Speaker 4: replace your doctor?
- 11:43Speaker 5: And the answer still is no. Their liability is still there.
- 11:46Speaker 5: You can't hold an AI machine responsible in a court
- 11:49Speaker 5: of law for something.
- 11:50Speaker 4: They don't have assets. You can't suit them per se.
- 11:53Speaker 5: They're not a person, but it's a tool that can
- 11:57Speaker 5: then ultimately can help us. And so from this specialty
- 12:00Speaker 5: pharmacies perspective, when you're considering and the lawyer is advising them,
- 12:04Speaker 5: when you're when you're considering, what do you do? A
- 12:07Speaker 5: solid set of policies and procedures and training on whatever
- 12:11Speaker 5: AI you decide to implement is absolutely critical and it
- 12:15Speaker 5: needs to be refreshed, constantly updated and monitored because as
- 12:19Speaker 5: the technology increases and evolves over time, regulations will eventually
- 12:25Speaker 5: keep coming and being developed and released and laws will
- 12:30Speaker 5: be passed, and so contemporary view of what AI can
- 12:35Speaker 5: do and where the limitations are is extremely critical for
- 12:38Speaker 5: your organization.
- 12:40Speaker 6: Absolutely, and I underscore that message for clinicians out there,
- 12:44Speaker 6: do not absent yourself from decision making. AI as a
- 12:47Speaker 6: tool is not replacing your judgment.
- 12:51Speaker 3: So, simon, you mentioned effects and reimbursement. Can you elaborate
- 12:54Speaker 3: a little bit on that, because reimbursement is such a
- 12:57Speaker 3: concern right for specialty pharmacy right now. Are you saying
- 13:01Speaker 3: that the use of AI would decrease reimbursement or what
- 13:04Speaker 3: do you mean by reimbursement?
- 13:06Speaker 6: Sure, so, as we see AI become a more frequent
- 13:09Speaker 6: tool in the clinician tool set, where you're going to
- 13:16Speaker 6: see changes, I think is as payers look for what
- 13:19Speaker 6: they're reimbursing and how involved the clinician is going to
- 13:23Speaker 6: be in the provision of services. Are they going to
- 13:26Speaker 6: want to pay for what AI is doing? Does that
- 13:30Speaker 6: decrease the amount that you pay for what the clinician
- 13:33Speaker 6: is doing. It's some of these like edge case issues,
- 13:36Speaker 6: the nuances that you get into as the AI develops
- 13:41Speaker 6: over time. I don't think we're there yet. We're just
- 13:43Speaker 6: kind of at the very beginning of this discussion. But
- 13:49Speaker 6: that's where my mind is going to Shila is just
- 13:51Speaker 6: understanding how payers are going to think about integration of
- 13:55Speaker 6: AI tools and how they get paid for. Right.
- 13:59Speaker 3: That's interesting too, right, because then how would you determine,
- 14:02Speaker 3: you know, what the threshold is, how much are we
- 14:04Speaker 3: going to pay? How much are we going to say
- 14:05Speaker 3: that is attributed to AI? And then of course that
- 14:07Speaker 3: would be different, right I'm thinking based on pharmacy size and.
- 14:10Speaker 6: Scale exactly, it could be very different depending on that,
- 14:14Speaker 6: even the tools that are available within an individual pharmacy
- 14:18Speaker 6: and the level of sophistication. And there's not, at least
- 14:21Speaker 6: not at present, there isn't a uniform standard for you know,
- 14:25Speaker 6: pharmacy A is going to use this AI tool and
- 14:28Speaker 6: it will be the same at pharmacy B. So as
- 14:30Speaker 6: you're a pair evaluating how much of this clinician's work
- 14:34Speaker 6: is being done by AI versus the clinician, you know,
- 14:37Speaker 6: untangling that I think is going to be a real challenge.
- 14:40Speaker 3: Sure, yeah, and I mean, and it's just it's dependent
- 14:43Speaker 3: on the on the pharmacists right comfort level. Like I
- 14:47Speaker 3: rewind a thousand years ago when I was working in
- 14:49Speaker 3: a community pharmacy, if you know, I used to float
- 14:51Speaker 3: from store to store sometimes and even in the store
- 14:54Speaker 3: a pharmacist comfort with you know, allowing technicians to do
- 14:58Speaker 3: certain things was different.
- 14:59Speaker 5: Right.
- 15:00Speaker 3: You would go into one store and they're like, oh
- 15:01Speaker 3: I do this, this and this, and then another store,
- 15:03Speaker 3: oh no, I'm not allowed to do that, and again
- 15:05Speaker 3: it was just the pharmacists preference, so they could be
- 15:07Speaker 3: the same here, right, absolutely, all right, So do you
- 15:14Speaker 3: anticipate or have legitimate concerns that the implementation of AI
- 15:18Speaker 3: into the healthcare space? We talked a lot about hip
- 15:20Speaker 3: and privacy, that there are potential privacy risks to the
- 15:23Speaker 3: patients personal information or on the flip side, right, is
- 15:27Speaker 3: this going to be a good thing, right? And is
- 15:29Speaker 3: it going to help achieve greater data privacy.
- 15:34Speaker 6: I think there's going to be some wins with AI
- 15:37Speaker 6: being deployed, ironically enough to further data privacy goals and
- 15:41Speaker 6: doing things like facilitating destruction of data planned destruction when
- 15:46Speaker 6: it's appropriate. But my take is, overall, is AI systems
- 15:50Speaker 6: accumulate and analyze vast, vast amounts of data, the risk
- 15:55Speaker 6: that that information and in the case of specialty pharmacy
- 15:59Speaker 6: where it's off and very sensitive information is going to
- 16:02Speaker 6: be accessed without the appropriate authorization either from the patient
- 16:05Speaker 6: or you know that there's bad actors involved or even
- 16:08Speaker 6: just ignorant actors involved that are using AI in a
- 16:11Speaker 6: way that's not anticipated, is going to create inappropriate uses.
- 16:15Speaker 6: So I think, on balance, we're going to see more risk.
- 16:21Speaker 5: Absolutely, and I think there's I look at it in
- 16:25Speaker 5: a couple different ways. When I talk to people about
- 16:27Speaker 5: how they're going to leverage AI in a practical manner,
- 16:31Speaker 5: I always ask them, well, what type of ecosystem is
- 16:34Speaker 5: the data exist? Again, because I explain chat GPT is
- 16:37Speaker 5: a volcano. When you throw something in chat GPT, you're.
- 16:40Speaker 4: Not getting it back out.
- 16:41Speaker 5: When you throw it into a volcano, you're not going
- 16:43Speaker 5: in there and grabbing it, so you lose it forever.
- 16:46Speaker 5: And in the case of a specialty pharmacy and really
- 16:49Speaker 5: any business, if you have somebody that goes onto chat
- 16:51Speaker 5: GPT and puts in a patient's PHI, that's the violation
- 16:55Speaker 5: because it's the PHI is leaving a secure environment and
- 16:59Speaker 5: going into the endless abyss of a computer system that
- 17:03Speaker 5: is going to take.
- 17:05Speaker 4: That data, analyze it, and then there's no way to
- 17:07Speaker 4: delete it.
- 17:08Speaker 5: Versus if you're implementing an AI system within your pharmacy
- 17:11Speaker 5: where you control the ecosystem, the data only stays within
- 17:14Speaker 5: your system, The system learns your data, it doesn't inform
- 17:18Speaker 5: any other organization, It cannot be accessed by outside parties.
- 17:22Speaker 4: Then the risks are generally a lot less. But really,
- 17:26Speaker 4: I think what we're going.
- 17:27Speaker 5: To end up seeing here within the next twelve to
- 17:30Speaker 5: twenty four months is some sort of push at the
- 17:33Speaker 5: federal level for a comprehensive AI data Privacy legislation agreement
- 17:41Speaker 5: giant bill that addresses some of the limitations and kind
- 17:46Speaker 5: of answers or clears up some of the questions that
- 17:48Speaker 5: people have. But table stakes for me is just remaining
- 17:52Speaker 5: compliant with HIPPA understanding and making sure that if you're
- 17:55Speaker 5: working with vendors or third parties that are going to
- 17:58Speaker 5: be helping you implement AI into your specialty pharmacy, you
- 18:02Speaker 5: make sure that they have the appropriate controls in place,
- 18:04Speaker 5: either ISO or SOCK two, and that you're continuing to
- 18:07Speaker 5: make sure that you're doing information security audits and working
- 18:10Speaker 5: closely with your INFOSEC teams to check for vulnerabilities, do
- 18:15Speaker 5: those tests, and keep up to date on the latest breaches,
- 18:19Speaker 5: because unfortunately, no matter how good we are or how
- 18:21Speaker 5: great our systems are, There's always going to be vulnerabilities,
- 18:25Speaker 5: and you never want to be the headline for the
- 18:29Speaker 5: latest Haacker breach.
- 18:32Speaker 6: I love that analogy, Candae of the volcano very app
- 18:37Speaker 6: and I echo your thoughts there. Effective data privacy policies,
- 18:40Speaker 6: cybersecurity protections are really going to help with consumer confidence
- 18:44Speaker 6: as we embark into more AI endeavors in the healthcare
- 18:47Speaker 6: space and the specialty pharmacy space, and Candas you had
- 18:51Speaker 6: also mentioned earlier that bipartisan House report that dropped yesterday
- 18:55Speaker 6: and alluded to the fact that you expect to see
- 18:57Speaker 6: more regulation, I think I do too. The House report
- 19:01Speaker 6: was pretty clear that there's agreement that AI has the
- 19:05Speaker 6: potential to exacerbate privacy harms. That seems to be that
- 19:09Speaker 6: seems to be not an issue that's in contention, and
- 19:13Speaker 6: that Americans have really I think what they said is
- 19:15Speaker 6: limited recourse for many of those harms, So they're looking
- 19:18Speaker 6: really at a solution that are.
- 19:20Speaker 3: Ablewn So, within the broader and ongoing discussion of AI implementation,
- 19:29Speaker 3: bias has been at the forefront of potential issues or complications.
- 19:33Speaker 3: How can those within the special de pharmacy space who
- 19:36Speaker 3: wish to implement AI work to prevent bias from becoming
- 19:40Speaker 3: an issue that leads to detrimental outcomes for patients.
- 19:48Speaker 5: So this one is this is a loaded question because
- 19:51Speaker 5: it really does depend a little bit on the systems
- 19:55Speaker 5: you're depending on using and also the patients you serve.
- 19:58Speaker 5: So I'll stick with the rare disease groups for a minute,
- 20:02Speaker 5: because bias tends to present heavily with small data sets,
- 20:06Speaker 5: and if you're serving rare, orphan patient.
- 20:09Speaker 4: Populations, this is going to be a problem for you.
- 20:12Speaker 5: And so, and it falls back into hippa data privacy
- 20:16Speaker 5: when we're putting data sets into AI machines to learn
- 20:21Speaker 5: and you have to strip out identifying information, you know,
- 20:24Speaker 5: let's say gender, race, Those important pieces of data can
- 20:29Speaker 5: impact clinical decision making for AI systems that are giving
- 20:32Speaker 5: you those outputs.
- 20:34Speaker 4: And in those situations, it's very difficult to.
- 20:38Speaker 5: Assess the accuracy of what an AI system, let's say
- 20:42Speaker 5: that's recommending a dosage or a treatment plan, or perhaps
- 20:47Speaker 5: a potential new medication or complementary medication. You can't really
- 20:52Speaker 5: rely on that because it's not taking a full look
- 20:54Speaker 5: at the patient population. And as we've seen, you know,
- 20:56Speaker 5: in the pharmacy space and overall with treatments and rare populations.
- 21:00Speaker 5: There's a lot of cases where what we assume would
- 21:03Speaker 5: work for a condition doesn't end up working. But if
- 21:07Speaker 5: your data sets are limited, you may not be able
- 21:09Speaker 5: to train that AI system to give you that accurate analysis.
- 21:13Speaker 5: And that's why we still depend on human decision making
- 21:17Speaker 5: to ultimately come to that final conclusion. But from my
- 21:20Speaker 5: perspective and in my experience, testing and auditing your systems
- 21:24Speaker 5: is really important. Running the tests, seeing if you can
- 21:27Speaker 5: ultimately break the system or get it to have a
- 21:31Speaker 5: bias is very critical. And then if you do, during
- 21:35Speaker 5: the course of testing discover that you need to have
- 21:38Speaker 5: a plan in place and a policy and procedure set
- 21:41Speaker 5: up to address that as quickly and as effectively as possible.
- 21:46Speaker 6: I totally agree with that, Candice. My simplistic summary of
- 21:50Speaker 6: this is garbage in, garbage out. You've got to have
- 21:53Speaker 6: good data in order to get a good output. So
- 21:55Speaker 6: underrepresentative data sets or data sets that incorporate bias in
- 21:59Speaker 6: them because they are only looking at a specific subset
- 22:03Speaker 6: of the population, are going to result in a poor output.
- 22:06Speaker 6: And then you can also see bias in the algorithm
- 22:09Speaker 6: like itself, so that testing and auditing process is really
- 22:12Speaker 6: really critical.
- 22:15Speaker 5: And one more thing that I always found very fascinating
- 22:19Speaker 5: and I was kind of I've tested a couple systems
- 22:21Speaker 5: in the past and found it to be true in
- 22:23Speaker 5: a friend of mine who's an expert in information security
- 22:26Speaker 5: was the one who shared it with me, was hallucinations
- 22:29Speaker 5: where sometimes AI systems will I would say, eat or
- 22:34Speaker 5: consume a data set and then see patterns there that
- 22:37Speaker 5: don't actually exist, which is a little frightening as an
- 22:41Speaker 5: attorney because you kind of just start going down the
- 22:43Speaker 5: rabbit hole while what if that happens, and what does
- 22:45Speaker 5: that mean and what kind of consequences could that lead to.
- 22:48Speaker 5: So that's where as attorneys you need to really get
- 22:51Speaker 5: in good with your tech and IT and INFOSEC folks
- 22:54Speaker 5: to make sure that you partner with them to better understand.
- 22:57Speaker 4: The testing and the updates for your systems.
- 23:02Speaker 5: And one thing that I did read within that Congressional
- 23:06Speaker 5: AI Task Force report that I was very happy to
- 23:08Speaker 5: see was even looking at federal data sets.
- 23:10Speaker 4: They were talking about sun setting legacy data.
- 23:13Speaker 5: And I think in the specialty pharmacy space, as science
- 23:16Speaker 5: is evolving, as we're getting better about treating patients with
- 23:19Speaker 5: let's say step therapies and frontline treatments and what's considered
- 23:24Speaker 5: the first treatment when a patient walks in at diagnosis first,
- 23:27Speaker 5: when they find that magical drug that makes their life better.
- 23:31Speaker 5: We have to be careful if we're inputting data into
- 23:34Speaker 5: these systems that's outdated because let's say, for like with
- 23:38Speaker 5: my rare disease prednozone used to be a frontline treatment.
- 23:41Speaker 5: They're kind of stepping away from that now. But if
- 23:43Speaker 5: you took a data set from patients with immune thrombocytopenia
- 23:46Speaker 5: and you put it into an AI system and it
- 23:48Speaker 5: was from ten to fifteen years ago, it wouldn't give
- 23:51Speaker 5: you the correct output like it would today when we
- 23:53Speaker 5: have so many more fdaproof therapies. And so that was
- 23:56Speaker 5: something I was very happy to see because from our
- 23:59Speaker 5: perspective specialty pharmacy space, that's a very critical consideration.
- 24:03Speaker 3: So within the specialty pharmacy space, where do you anticipate
- 24:07Speaker 3: that AI will provide the greatest benefit.
- 24:09Speaker 6: I think that we're already seeing leaps forward in prior
- 24:13Speaker 6: authorization advances and claims adjudication possibilities for identification and prevention
- 24:21Speaker 6: of errors, and I think we're going to see more
- 24:24Speaker 6: in spaces like diversion control and slightly more generally, I
- 24:29Speaker 6: think the AI has just amazing applications for personalized medicine
- 24:33Speaker 6: and how that's going to bleed over to specialty pharmacy
- 24:35Speaker 6: and more personalized treatment protocols and actual medications, the development
- 24:42Speaker 6: of a medication that's for small or for candae. I
- 24:45Speaker 6: think we're going to see more of that, using the
- 24:49Speaker 6: patient's genomic and medical data to create these very customized
- 24:53Speaker 6: treatment plans. Predictive modeling, I think is another powerful one,
- 24:58Speaker 6: and having AI generate models that predict things like disease
- 25:01Speaker 6: progression and drug efficacy. So as a pharmacist, that's going
- 25:04Speaker 6: to be a really useful tool when you can look
- 25:06Speaker 6: at and see like this is really going to be
- 25:09Speaker 6: the frontline therapy and helping educate the prescriber and be
- 25:13Speaker 6: on the front lines of those discussions and looking at
- 25:16Speaker 6: things like toxicity studies. I think that's going to be
- 25:18Speaker 6: really a useful tool in this space. And I think
- 25:21Speaker 6: that also we're going to see a lot more synthetic
- 25:23Speaker 6: biology that comes out, and so pharmacists are going to
- 25:28Speaker 6: have to grapple with these new types of products as
- 25:32Speaker 6: AI is used to design and optimize these new biological systems.
- 25:38Speaker 5: Yeah, and for me, I see the first thing that
- 25:40Speaker 5: I hear about from friends is that they've seen AI
- 25:43Speaker 5: working its magic and supply chain and being able to
- 25:46Speaker 5: sort of help with a lot of automated systems for
- 25:49Speaker 5: inventory management and some of the just i'd say, just
- 25:53Speaker 5: downright annoying day and day out tasks. So you had
- 25:55Speaker 5: to sit it a computer, click buttons, input basic information,
- 26:00Speaker 5: take up a lot of time and aren't necessarily things
- 26:03Speaker 5: that drive revenue and growth for specialty pharmacies. But from
- 26:07Speaker 5: my perspective, especially in my professional career right now, patient support.
- 26:12Speaker 4: Is going to be a huge benefactor of artificial intelligence.
- 26:15Speaker 5: I think we've seen an explosion of AI virtual assistance.
- 26:19Speaker 5: I actually worked on one most recently for Metadvisor Solutions,
- 26:23Speaker 5: which has been a lot of fun and really exciting.
- 26:26Speaker 5: You're going to see AI helping with patients dealing with
- 26:29Speaker 5: prescription refills, accessing that accompanying information and safety information for
- 26:34Speaker 5: their medications, and then also scheduling appointments or being able
- 26:38Speaker 5: to connect with the pharmacist instead of waiting on hold
- 26:41Speaker 5: for your pharmacy to.
- 26:42Speaker 4: Get on the phone and chat with you. Being able to.
- 26:45Speaker 5: Access support through an AI bot is going to, I think,
- 26:51Speaker 5: radically change the way that patients are interacting with their
- 26:54Speaker 5: pharmacies within the next two to five years.
- 26:57Speaker 6: Right, and improve accessibility because those bots can be program
- 27:01Speaker 6: to speak in the patient's first language, right, and be
- 27:04Speaker 6: instantly available. There's no wait for the translator, there's no
- 27:09Speaker 6: here's your scrap of paper with information in your first language.
- 27:12Speaker 6: So yeah, the potential for greater access to care and
- 27:17Speaker 6: equalizing access to care is amazing.
- 27:22Speaker 4: I think we have to be careful though, right.
- 27:23Speaker 3: It's so funny because I was just I was in
- 27:25Speaker 3: kind of a scenario where I was talking with the bot,
- 27:26Speaker 3: and I didn't want to be talking to the bot,
- 27:28Speaker 3: but I couldn't get out of that, right, I wanted
- 27:29Speaker 3: to talk to a person. I was so frustrated. And
- 27:33Speaker 3: this is not healthcare related, right, which I think is
- 27:35Speaker 3: so much more personal, right, And people they don't need
- 27:38Speaker 3: added layers of frustration when dealing with, you know, situations,
- 27:42Speaker 3: especially specialty pharmacy type situations. But oh my gosh, it
- 27:45Speaker 3: was so frustrating. I just hung up. I was like,
- 27:47Speaker 3: forget it, I'll just do it a different way. So,
- 27:51Speaker 3: but I mean lots of you know, I guess, lots
- 27:53Speaker 3: of room for opportunity and customization, right.
- 28:00Speaker 6: Yep. And I think that those technologies the pain point Sheila,
- 28:02Speaker 6: They're going to get smoothed over time, at least that's
- 28:06Speaker 6: my hope.
- 28:07Speaker 3: Rightly, with the rapid development of AI in the healthcare sector,
- 28:12Speaker 3: as we've been chatting about how can specialty pharmacies ensure
- 28:16Speaker 3: that they stay compliant with evolving regulations and avoid legal pitfalls.
- 28:20Speaker 6: I think that the obvious one is you know, know
- 28:24Speaker 6: your experts and bring in counsel, make sure, as Candace
- 28:28Speaker 6: mentioned earlier, you've got your IT folks engaged, that you're
- 28:32Speaker 6: bringing the right stakeholders to the table to have meaningful
- 28:35Speaker 6: conversations and help you stay abreast of changing conditions and
- 28:40Speaker 6: uncertain regulatory landscape, developments and technology. What are the best
- 28:44Speaker 6: industry practices? I think that the gold standard right now
- 28:47Speaker 6: in terms of development for age AI is managing the
- 28:52Speaker 6: to the NIS risk Management framework and making sure that
- 28:56Speaker 6: that's built into your organization, that your compliance team is
- 28:59Speaker 6: aware of that and thinking about those steps.
- 29:03Speaker 5: Yeah, And I'd say, you know, either asking your legal counsel,
- 29:06Speaker 5: or you're building some sort of internal working group to
- 29:09Speaker 5: regulator monitor monitor regulatory updates. I think we're going to
- 29:15Speaker 5: see a lot more coming out of FDA and HHS
- 29:18Speaker 5: in the next year regarding this, and if you have
- 29:22Speaker 5: government relations professionals within your organization, definitely tap them. As
- 29:27Speaker 5: with any new and emerging technology or area of the law,
- 29:31Speaker 5: there's a lot of opportunity to have your voice heard
- 29:34Speaker 5: about at the state and federal level by regulators who
- 29:37Speaker 5: are looking to enact policies. I tell people all the time,
- 29:41Speaker 5: do not discount the notice and comment period for executive
- 29:45Speaker 5: agencies when they're looking for input for role making. Those
- 29:49Speaker 5: are really critical times to have your voice heard. And obviously,
- 29:52Speaker 5: working you know, with NASP and working with our I'll
- 29:55Speaker 5: plug the Government Affairs Group because I'm a member of
- 29:58Speaker 5: that and they do amazing work making sure that you're
- 30:02Speaker 5: participating in our groups and participating in like Legal Day
- 30:07Speaker 5: at our annual conference. That's very, very critical because those
- 30:11Speaker 5: are going to be the times that you get an
- 30:13Speaker 5: opportunity to make sure that you're kind of staying ahead
- 30:15Speaker 5: of what's coming. And at the end of the day,
- 30:18Speaker 5: none of us know for sure what's on the horizon.
- 30:20Speaker 5: But being able to be flexible, having the finger on
- 30:24Speaker 5: the pulse of your organization and the understanding that your
- 30:28Speaker 5: employees are going to need to have training and regular
- 30:31Speaker 5: policy updates and briefings is very critical.
- 30:34Speaker 4: And I, as in.
- 30:35Speaker 5: House counsel, have an open door policy. Anybody can come
- 30:38Speaker 5: to me anytime with questions. No question is stupid. I
- 30:42Speaker 5: like to engage in conversation around artificial intelligence and the
- 30:46Speaker 5: potential to continue using it as a day to day
- 30:51Speaker 5: beneficial tool to streamline processes and improve our workflows. I
- 30:55Speaker 5: think those are just things that we have to keep
- 30:57Speaker 5: an open mind going forward. But also remain as the
- 31:00Speaker 5: fact that these are very powerful machines that while they
- 31:04Speaker 5: have the ability to do good things, they also have
- 31:06Speaker 5: the ability to get us into a lot of trouble
- 31:09Speaker 5: if we're not very careful.
- 31:11Speaker 3: So now let's take out our crystal balls and can
- 31:14Speaker 3: you share any glimpses of what the future might hold
- 31:18Speaker 3: for AI and healthcare?
- 31:20Speaker 6: Well, these are some of my favorite questions, Sheila, What
- 31:23Speaker 6: will the future hold? So the practical thing is, I
- 31:27Speaker 6: think that healthcare is almost universally identified as one of
- 31:30Speaker 6: the top areas with the most significant aid potential, So
- 31:34Speaker 6: I predict gains and research and diagnosis and treatment, both
- 31:38Speaker 6: in efficiency and efficacy. But the really fun stuff. The
- 31:43Speaker 6: Pew Research Center surveyed a number of AI experts on
- 31:46Speaker 6: what the future of AI holds, and I love talking
- 31:49Speaker 6: about some of their predictions because they sort of blow
- 31:52Speaker 6: my mind and it sounds like sci fi. But I
- 31:54Speaker 6: do think that this is the direction things are trending.
- 31:56Speaker 6: So if you'll indulge me, I'll share a few and
- 31:58Speaker 6: then I'll let hand us share her thoughts. But some
- 32:01Speaker 6: of their predictions include things like emotional companion robots, so
- 32:05Speaker 6: robots that have visual interfaces that can mirror our own
- 32:09Speaker 6: emotions and will help us with tasks like child rearing.
- 32:13Speaker 6: They're also talking about direct brain to computer interfaces in
- 32:17Speaker 6: digital body implants that will buy by some predictions twenty
- 32:21Speaker 6: thirty five, so not that distant future begin to be
- 32:24Speaker 6: beneficial and commercially viable. And then things like smart eyewear
- 32:29Speaker 6: and earbuds. So imagine you're wearing a pair of glasses
- 32:32Speaker 6: that provides you with a computer like digital display of
- 32:36Speaker 6: your environment and research in real time about the people
- 32:39Speaker 6: around you. So researchers at Stanford right now are developing
- 32:43Speaker 6: what they call a nanophotonic metasurface waveguide that allows for
- 32:48Speaker 6: the viewing of full color three D images on glasses
- 32:51Speaker 6: right now. So it all sounds very futuristic, but I
- 32:54Speaker 6: think that we're on the doorstep of some of these things,
- 32:57Speaker 6: which is really cool.
- 33:00Speaker 4: That's interesting.
- 33:01Speaker 3: The emotional support robot, So I was thinking, now, I
- 33:03Speaker 3: don't know if it's just like a virtual type thing
- 33:05Speaker 3: or if it's an actually you know how like they
- 33:06Speaker 3: have some of those robots for like patient compliance, they
- 33:09Speaker 3: help and they chat with the person. So I'm thinking
- 33:11Speaker 3: like on an airplane where they have to buy a
- 33:13Speaker 3: seat for their robot, or can incidental if a real.
- 33:17Speaker 6: Problems and questions that we will have to grapple with Shiela.
- 33:20Speaker 6: But I mean, you can see that the potential in
- 33:23Speaker 6: in pharmacy even you know, if you have a robot
- 33:26Speaker 6: that's able to interact with the patient and you know
- 33:28Speaker 6: they can see them on like a team's chat and
- 33:32Speaker 6: they can actually the robots emotions. You know, they're face,
- 33:35Speaker 6: they have a face and it's mirroring the patient's emotions
- 33:38Speaker 6: and you know when the patient is upset and the
- 33:40Speaker 6: robot's able to mirror that and show that they're upset too,
- 33:43Speaker 6: and like they're empathizing.
- 33:45Speaker 1: Uh.
- 33:46Speaker 6: It's very powerful to think about where some of these
- 33:48Speaker 6: things might be able to support patient care.
- 33:52Speaker 3: So cool.
- 33:54Speaker 5: Yeah, and I think we're going to see a rapid
- 33:57Speaker 5: increase in real time patient monit, especially for patients that
- 34:02Speaker 5: may be taking medications that dosage could vary depending on
- 34:07Speaker 5: disease severity. I like to think of, like my fellow
- 34:09Speaker 5: blood disorder community, a lot of us have to have
- 34:12Speaker 5: our blood taken so often, and one thing we always
- 34:15Speaker 5: talk about is, oh, could there ever be a situation
- 34:17Speaker 5: where like maybe there is an implant or something that
- 34:20Speaker 5: we have that can give a live platelet count, or
- 34:23Speaker 5: do we need to have factor this week or not.
- 34:26Speaker 4: And being able.
- 34:27Speaker 5: To reduce the burden of having to visit the phlebotomist
- 34:30Speaker 5: every couple days or every week and wait in line
- 34:34Speaker 5: and just have the data set provided to your hematologists
- 34:38Speaker 5: or your rheumatologists would be fantastic. Another thing I think
- 34:41Speaker 5: we're really going to see and there'll be regulations for this,
- 34:44Speaker 5: so I try to temper my excitement is decision making
- 34:48Speaker 5: support for pharmacists and for doctors and being able to
- 34:52Speaker 5: have an extra set of eyes per se via a
- 34:55Speaker 5: computer to make sure that there's no drug interactions or
- 34:59Speaker 5: that it provides some sort of nutrition or dietary support
- 35:03Speaker 5: for medications.
- 35:04Speaker 4: I think that's one thing that we don't.
- 35:06Speaker 5: Get a lot of right now, is when I visit
- 35:07Speaker 5: my pharmacy and I talk to my pharmacists about the
- 35:09Speaker 5: medications I'm taking, I'll sometimes ask like, so, are there
- 35:12Speaker 5: any foods that I should avoid? And it's like, well,
- 35:15Speaker 5: the paperwork doesn't say that you should, but I have
- 35:18Speaker 5: heard patients that have taken this say that you should
- 35:20Speaker 5: avoid this or that, or they've had a reaction with this.
- 35:23Speaker 5: And sometimes that's really dependent on the pharmacist at the
- 35:26Speaker 5: counter when you pick up your medication that you're talking
- 35:28Speaker 5: to and if they've had that experience. But once we
- 35:30Speaker 5: get AI more widely adopted in the pharmacy setting, I
- 35:34Speaker 5: think we'll be able to see and incorporate patient feedback
- 35:37Speaker 5: points into those AI clinical support mechanisms that should be
- 35:43Speaker 5: able to provide more personalized and tailored advice or pointers
- 35:48Speaker 5: for the pharmacists to provide to patients to help support
- 35:52Speaker 5: them along their journey.
- 35:55Speaker 3: Yeah, that gets me thinking when you're talking about you know,
- 35:57Speaker 3: like the lab value, it's kind of like you know,
- 36:00Speaker 3: continuous bluecost monitor, right exactly.
- 36:03Speaker 5: Yes, we are very envious of those who are able
- 36:06Speaker 5: to do that and avoid the constant phlebotomy visits. And
- 36:11Speaker 5: I can tell you is somebody that regularly has to
- 36:13Speaker 5: go and have about sixteen vials taken at a time.
- 36:15Speaker 5: It is very nice to dream of the world where
- 36:19Speaker 5: maybe that doesn't have to happen. And it takes a
- 36:20Speaker 5: significant amount of time out of your days and weeks,
- 36:23Speaker 5: and then when you add it up, it's it's a
- 36:24Speaker 5: lot of hours.
- 36:25Speaker 4: To dedicate to that.
- 36:27Speaker 5: And so there is always hope that that technology is
- 36:31Speaker 5: around the corner.
- 36:33Speaker 3: Sure, and even just being able to have you know,
- 36:37Speaker 3: a look into the patient real time right versus jeez,
- 36:41Speaker 3: I was having a crisis on Monday, got the blood
- 36:43Speaker 3: work done early Tuesday morning, got the results back, you
- 36:46Speaker 3: know what I mean, Tuesday afternoon. If you could intervene
- 36:48Speaker 3: right away, yes, that would be that would be really
- 36:52Speaker 3: really cool.
- 36:53Speaker 5: It also would be nice to be able to provide
- 36:54Speaker 5: that data to a pharmacist at the counter, because I've
- 36:56Speaker 5: had several times where I've had to take an antibiotic
- 36:59Speaker 5: or something temporarily and they ask me, well, I see
- 37:02Speaker 5: here you have a low platelet disorder. What's your platelets at?
- 37:05Speaker 5: And I'm like, oh, I don't know.
- 37:06Speaker 4: I haven't had and tested in the last like forty
- 37:08Speaker 4: eight hours.
- 37:09Speaker 5: And so if you're able to provide that, then the
- 37:11Speaker 5: you know, and the pharmacists may look at that information
- 37:13Speaker 5: or data for whatever it is that they have to consider,
- 37:16Speaker 5: and if there's some real time information that can be provided,
- 37:19Speaker 5: they may be able to make a better decision for
- 37:21Speaker 5: a medication that could suit the patient and not put
- 37:25Speaker 5: them at additional risk of an adverse enter side effect.
- 37:28Speaker 3: Yeah, and what we were talked about a little bit earlier, right,
- 37:30Speaker 3: that personalized precision type care.
- 37:34Speaker 6: Yeah, President type care for sure. And it raises a
- 37:36Speaker 6: whole other topic shield, which is interoperability. So, once we've
- 37:40Speaker 6: got the data and we've got the AI in certain spots,
- 37:44Speaker 6: how do we really leverage it across the healthcare system?
- 37:47Speaker 6: How do we make sure that different systems can talk
- 37:49Speaker 6: to each other. A lot of this data is not
- 37:52Speaker 6: stored in a uniform way. We have data locked up
- 37:54Speaker 6: in different places. How do we ensure that it's flowing
- 37:58Speaker 6: to the right place is in the right time to
- 38:00Speaker 6: really maximize the ability to providetient patient care in the moment.
- 38:05Speaker 4: I think about that a lot.
- 38:06Speaker 3: To moment I'm thinking the key I think is the patient, Right,
- 38:09Speaker 3: the patient needs to be walking around with their own data,
- 38:12Speaker 3: so that then wherever they present, they could just I
- 38:14Speaker 3: don't know if it's on their phone or whatever, but
- 38:15Speaker 3: oh here I am, here's what's going on.
- 38:18Speaker 4: Right.
- 38:19Speaker 6: Yeah, I think that would be ideal and it aligns
- 38:22Speaker 6: with I think one of the core ideas with AI
- 38:26Speaker 6: regulation is that the patient be in charge of their
- 38:29Speaker 6: data or have of ways and their data, have control
- 38:31Speaker 6: of what is happening with their data. So if you,
- 38:34Speaker 6: as the patient can present in the moment, have like
- 38:37Speaker 6: the suitcase of virtual data with you at all times,
- 38:39Speaker 6: like this is me, here's my student.
- 38:42Speaker 4: Absolutely, I think that would be incredible. Yeah.
- 38:46Speaker 5: I've been talking to several rare disease patient organizations that
- 38:50Speaker 5: have like natural history studies going or they're collecting patient
- 38:54Speaker 5: data for drug development, and there's been a conversation about
- 38:57Speaker 5: if we're collecting all this data, could we leverage these
- 39:00Speaker 5: data sets for AI. Could they help with in addition
- 39:03Speaker 5: to running drug discovery and you know, using the drug
- 39:06Speaker 5: library to find.
- 39:07Speaker 4: Maybe a small molecule that will work.
- 39:09Speaker 5: Could we leverage the data for AI to help with
- 39:12Speaker 5: some sort of clinical decision making. And so I always say, hey,
- 39:15Speaker 5: if you can collect the data sets and get the
- 39:17Speaker 5: permission from patients to perhaps build something out that that
- 39:21Speaker 5: can assist in the future as well. And there's obviously
- 39:24Speaker 5: power and numbers when you're able to get a data
- 39:27Speaker 5: set together, even in small patient populations, and be able
- 39:31Speaker 5: to contribute that potentially to the next generation of software
- 39:35Speaker 5: that can serve your community.
- 39:37Speaker 3: Sure, I'm even thinking about, you know, if you're a
- 39:39Speaker 3: member of you know, health Plan X today and then
- 39:41Speaker 3: you move to Y and then we start all over, right,
- 39:44Speaker 3: because they don't know about you, and then they're questioning
- 39:46Speaker 3: your medications and what have you tried? Or like lots
- 39:48Speaker 3: of times when you go to the doctor, they'll ask me, well,
- 39:50Speaker 3: when did you have these surgeries? I don't know, right,
- 39:53Speaker 3: like sometime between you know, day one and today, I
- 39:56Speaker 3: had all of these things done. So I just think
- 39:58Speaker 3: it would just it would just be so much more helpful,
- 40:01Speaker 3: right and probably prevent a lot of like duplication and
- 40:04Speaker 3: waste and.
- 40:05Speaker 6: Frustration right, and having smart tools to be able to
- 40:09Speaker 6: query information in these larger and larger data sets so
- 40:12Speaker 6: the clinician can ask queries of the data in real time.
- 40:16Speaker 6: When did Sheila have this surgery? And having the answer up.
- 40:22Speaker 3: Sheill is not smart enough to remember, but yeah, oh
- 40:25Speaker 3: my gosh, so much to think about. I can't thank
- 40:28Speaker 3: you both enough for chatting with me and sharing this
- 40:31Speaker 3: valuable information.
- 40:34Speaker 6: It was mackey for Sheila. I'm always happy to be
- 40:36Speaker 6: on any call with you and Canvas awesome.
- 40:40Speaker 3: Well, we will continue the discussion, I'm sure, as this
- 40:42Speaker 3: continues to evolve, And as a reminder, NASP corporate members
- 40:47Speaker 3: are invited to be my guest on one complimentary podcast
- 40:49Speaker 3: per year. For more information about this or other NASP
- 40:53Speaker 3: membership benefits and events, please feel free to reach out
- 40:56Speaker 3: to membership at naspnet dot org or visit our website
- 41:01Speaker 3: www dot n A, S P N E T dot
- 41:05Speaker 3: O r G. Until next time, have a great day.
- 41:13Speaker 6: M hmm